NYSE:BSX - Boston Scientific Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$35.44 -0.45 (-1.25 %)
(As of 04/24/2019 04:00 PM ET)
Previous Close$35.89
Today's Range$34.7850 - $36.14
52-Week Range$27.91 - $41.00
Volume19.52 million shs
Average Volume7.80 million shs
Market Capitalization$49.28 billion
P/E Ratio24.11
Dividend YieldN/A
Beta0.87
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP10113710
Phone508-683-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.82 billion
Cash Flow$2.1809 per share
Book Value$6.31 per share

Profitability

Net Income$1.67 billion

Miscellaneous

Employees32,000
Outstanding Shares1,390,500,000
Market Cap$49.28 billion
Next Earnings Date4/24/2019 (Confirmed)
OptionableOptionable

Boston Scientific (NYSE:BSX) Frequently Asked Questions

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) issued its quarterly earnings data on Wednesday, April, 24th. The medical equipment provider reported $0.35 EPS for the quarter, missing analysts' consensus estimates of $0.36 by $0.01. The medical equipment provider had revenue of $2.49 billion for the quarter, compared to analyst estimates of $2.54 billion. Boston Scientific had a return on equity of 25.92% and a net margin of 17.01%. The company's revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.33 earnings per share. View Boston Scientific's Earnings History.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific issued an update on its FY19 earnings guidance on Wednesday, April, 24th. The company provided earnings per share guidance of $1.54-1.58 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.56. The company issued revenue guidance of +7-8% to $10.51-10.61 billion, compared to the consensus revenue estimate of $10.66 billion.Boston Scientific also updated its FY 2019 guidance to $1.54-1.58 EPS.

What price target have analysts set for BSX?

24 equities research analysts have issued 12-month target prices for Boston Scientific's shares. Their forecasts range from $32.00 to $48.00. On average, they anticipate Boston Scientific's stock price to reach $41.00 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price. View Analyst Price Targets for Boston Scientific.

What is the consensus analysts' recommendation for Boston Scientific?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 20 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:
  • 1. Needham & Company LLC analysts commented, "BSX’s 4Q18 revenue was in line with its 1/8/19 preannouncement while its EPS beat consensus. Management provided 2019 revenue guidance that bracketed consensus and adjusted EPS guidance that was below consensus at its mid-point. BSX’s organic revenue growth slowed to 7% in 3Q18 from 9% in 3Q18 given a more difficult comp. BSX’s operating margin was down 10 bps Y/ Y despite a 70 bps gross margin FX tailwind. Importantly, management indicated that Lotus Edge should be launched in the US in early 2Q19 and that they expect structural heart sales of $700-725M in 2019 which is up ~50% from 2018. Given BSX’s above-peer organic revenue growth, strong product pipeline, and potential for upside to estimates, we reiterate our Strong Buy rating." (2/6/2019)
  • 2. According to Zacks Investment Research, "Boston Scientific is suffering from significant cost escalation, which is weighing on its margins. Also, delay in LOTUS relaunch is hampering sales through 2018. Declining worldwide pacemaker sales is also hurting the CRM business. On a brighter note, the company is seeing growth across all business lines and geographies. Boston Scientific received a number of FDA approvals within the Cardiovascular group. This apart, it launched LithoVue within Urology and rolled out the GUIDE XT in Europe. We look forward to the three recent acquisitions- Claret Medical, VENITI and Augmenix. These are expected to strongly contribute to the company’s inorganic growth profile. Boston Scientific’s significant progress related to its LOTUS valve relaunch encourages us. Also, post the suspension of LOTUS valve in Europe, ACURATE TAVR continues to build momentum. Over the past three months, Boston Scientific outperformed its industry." (1/7/2019)
  • 3. BTIG Research analysts commented, "Sure Why BSX Buy BSX will acquire BTG plc (BTG-GB, Not Rated) for ~$4B. BTG is in of sales in the U.S. BTG focuses on interventional medicine (oncology and vascular) and also has a pharma division. We are not sure why BSX is trading down ~3%, which is about $1B. This makes little sense to us on a $4B deal. We see the interventional space as a high growth area and oncology/vascular fit within BSX salesforces. BSX has used capital well buying Asthmatx recently. Between this track record and consistently hitting targets, we thought BSX would have leeway with investors to make purchases. BTG’s business OUS, we see this deal as similar to AMS, which has been hugely successful for BSX as it has expanded sales OUS. We feel this deal should benefit BSX’s interventional business like AMMD added growth to urology." (11/21/2018)

Has Boston Scientific been receiving favorable news coverage?

Press coverage about BSX stock has been trending positive recently, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Boston Scientific earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.

Who are some of Boston Scientific's key competitors?

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include Netflix (NFLX), Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Bank of America (BAC), CVS Health (CVS), Gilead Sciences (GILD), Visa (V), Intel (INTC) and Boeing (BA).

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the folowing people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 54)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 53)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 55)
  • Mr. David A. Pierce, Exec. VP & Pres of MedSurg (Age 55)
  • Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 46)

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Retirement Systems of Alabama (0.09%), Atalanta Sosnoff Capital LLC (0.09%), Columbus Circle Investors (0.06%), Gateway Investment Advisers LLC (0.06%), Strs Ohio (0.05%) and Nisa Investment Advisors LLC (0.03%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun, Wendy Carruthers, Xin Warren Wang and Yoshiaki Fujimori. View Institutional Ownership Trends for Boston Scientific.

Which major investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including Barometer Capital Management Inc., Moody Lynn & Lieberson LLC, Columbus Circle Investors, Hodges Capital Management Inc., TIAA FSB, Sumitomo Life Insurance Co., State of Alaska Department of Revenue and First Quadrant L P CA. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Xin Warren Wang and Yoshiaki Fujimori. View Insider Buying and Selling for Boston Scientific.

Which major investors are buying Boston Scientific stock?

BSX stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Northpointe Capital LLC, Exane Derivatives, Deltec Asset Management LLC, QUANTRES ASSET MANAGEMENT Ltd, Bank of Edwardsville, NuWave Investment Management LLC and Mercer Global Advisors Inc. ADV. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $35.44.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $49.28 billion and generates $9.82 billion in revenue each year. The medical equipment provider earns $1.67 billion in net income (profit) each year or $1.47 on an earnings per share basis. Boston Scientific employs 32,000 workers across the globe.

What is Boston Scientific's official website?

The official website for Boston Scientific is http://www.bostonscientific.com.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]


MarketBeat Community Rating for Boston Scientific (NYSE BSX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  759 (Vote Outperform)
Underperform Votes:  657 (Vote Underperform)
Total Votes:  1,416
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Featured Article: What is the QQQ ETF?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel